152 related articles for article (PubMed ID: 28599981)
1. p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis.
Theodosakis N; Micevic G; Langdon CG; Ventura A; Means R; Stern DF; Bosenberg MW
J Invest Dermatol; 2017 Oct; 137(10):2187-2196. PubMed ID: 28599981
[TBL] [Abstract][Full Text] [Related]
2. Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase.
Kosnopfel C; Sinnberg T; Sauer B; Niessner H; Schmitt A; Makino E; Forschner A; Hailfinger S; Garbe C; Schittek B
Oncotarget; 2017 May; 8(22):35761-35775. PubMed ID: 28415756
[TBL] [Abstract][Full Text] [Related]
3. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.
Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG
Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202
[TBL] [Abstract][Full Text] [Related]
4. Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation.
Grasso S; Tristante E; Saceda M; Carbonell P; Mayor-López L; Carballo-Santana M; Carrasco-García E; Rocamora-Reverte L; García-Morales P; Carballo F; Ferragut JA; Martínez-Lacaci I
Neoplasia; 2014 Oct; 16(10):845-60. PubMed ID: 25379021
[TBL] [Abstract][Full Text] [Related]
5. HI-511 overcomes melanoma drug resistance
Chang X; Zhang T; Wang Q; Rathore MG; Reddy K; Chen H; Shin SH; Ma WY; Bode AM; Dong Z
Theranostics; 2020; 10(21):9721-9740. PubMed ID: 32863956
[No Abstract] [Full Text] [Related]
6. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
7. Discontinuing MEK inhibitors in tumor cells with an acquired resistance increases migration and invasion.
Nörz D; Grottke A; Bach J; Herzberger C; Hofmann BT; Nashan B; Jücker M; Ewald F
Cell Signal; 2015 Nov; 27(11):2191-200. PubMed ID: 26210887
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
[TBL] [Abstract][Full Text] [Related]
9. RSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growth.
Romeo Y; Moreau J; Zindy PJ; Saba-El-Leil M; Lavoie G; Dandachi F; Baptissart M; Borden KLB; Meloche S; Roux PP
Oncogene; 2013 Jun; 32(24):2917-2926. PubMed ID: 22797077
[TBL] [Abstract][Full Text] [Related]
10. The p90 ribosomal S6 kinase (RSK) inhibitor BI-D1870 prevents gamma irradiation-induced apoptosis and mediates senescence via RSK- and p53-independent accumulation of p21WAF1/CIP1.
Neise D; Sohn D; Stefanski A; Goto H; Inagaki M; Wesselborg S; Budach W; Stühler K; Jänicke RU
Cell Death Dis; 2013 Oct; 4(10):e859. PubMed ID: 24136223
[TBL] [Abstract][Full Text] [Related]
11. Rescue of cell cycle progression in BRAF
Toress-Collado AX; Nazarian R; Jazirehi AR
Tumour Biol; 2017 Sep; 39(9):1010428317721620. PubMed ID: 28936920
[TBL] [Abstract][Full Text] [Related]
12. Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner.
Roffé M; Lupinacci FC; Soares LC; Hajj GN; Martins VR
Cell Signal; 2015 Aug; 27(8):1630-42. PubMed ID: 25889895
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion.
Kosnopfel C; Wendlinger S; Niessner H; Siewert J; Sinnberg T; Hofmann A; Wohlfarth J; Schrama D; Berthold M; Siedel C; Sauer B; Jayanthan A; Lenz G; Dunn SE; Schilling B; Schittek B
J Exp Clin Cancer Res; 2023 Jul; 42(1):175. PubMed ID: 37464364
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of p90 ribosomal S6 kinase potentiates cisplatin activity in A549 human lung adenocarcinoma cells.
Abdulrahman N; Siveen KS; Joseph JM; Osman A; Yalcin HC; Hasan A; Uddin S; Mraiche F
J Pharm Pharmacol; 2020 Nov; 72(11):1536-1545. PubMed ID: 32667058
[TBL] [Abstract][Full Text] [Related]
15. Overcoming resistance to Sonic Hedgehog inhibition by targeting p90 ribosomal S6 kinase in pediatric medulloblastoma.
Pambid MR; Berns R; Adomat HH; Hu K; Triscott J; Maurer N; Zisman N; Ramaswamy V; Hawkins CE; Taylor MD; Dunham C; Guns E; Dunn SE
Pediatr Blood Cancer; 2014 Jan; 61(1):107-15. PubMed ID: 23940083
[TBL] [Abstract][Full Text] [Related]
16. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
17.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
18. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
[TBL] [Abstract][Full Text] [Related]
19. RSK promotes G2 DNA damage checkpoint silencing and participates in melanoma chemoresistance.
Ray-David H; Romeo Y; Lavoie G; Déléris P; Tcherkezian J; Galan JA; Roux PP
Oncogene; 2013 Sep; 32(38):4480-9. PubMed ID: 23108403
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of p90 ribosomal S6 kinase attenuates cell migration and proliferation of the human lung adenocarcinoma through phospho-GSK-3β and osteopontin.
Abdulrahman N; Jaballah M; Poomakkoth N; Riaz S; Abdelaziz S; Issa A; Mraiche F
Mol Cell Biochem; 2016 Jul; 418(1-2):21-9. PubMed ID: 27236820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
